Fig. 3From: Comparative effectiveness of recombinant human follicle-stimulating hormone alfa (r-hFSH-alfa) versus highly purified urinary human menopausal gonadotropin (hMG HP) in assisted reproductive technology (ART) treatments: a non-interventional study in GermanyPrimary outcomes in the overall population adjusted for possible confounding factors. Differences between study groups were adjusted for possible baseline confounding factors (age, BMI, type of infertility, GnRH protocol, year of first cycle and IVF centre) via inverse probability of treatment weighting using a propensity score estimated by boosted regression trees. Data were also adjusted for the following post-treatment variables: duration of OS, type of luteal support, type of ART treatment and the drug used to trigger ovulation. Data were analysed cumulatively (i.e. a complete cycle included all fresh and frozen transfers following a single stimulation cycle). HR, hazard ratio; RR, relative riskBack to article page